The European Association of Health Economics (EuhEA) conference organized by the Hamburg Center for Health Economics is starting tomorrow. During a session on drug innovation,  I will assess the feedback effects that post launch policies have on incentives for innovation, looking at the special case of orphan drug legislation. Especially, an empirical financial analysis of investment attractiveness in Orphan Drug R&D will be presented focusing on the US market.